- Home
- / Allogene Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Allogene Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.8
2024-10-29
Market Capitalization
$585.5 M
2024-10-29
Revenue
$22 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Revenue | 243.0K | 95.0K | 22.0K | |
| General and administrative expense | 79.3M | 71.7M | 65.2M | 56.8M |
| Operating expense total | 335.7M | 327.8M | 273.2M | 206.9M |
| EBIT | (335.4M) | (327.7M) | (273.2M) | (209.3M) |
| EBIT margin, % | -138044.9% | -344986.3% | -1241813.6% | |
| Interest income | 4.6M | 18.3M | 20.2M | 19.3M |
| Interest expense | 181.0K | |||
| Pre tax profit | (257.1M) | (190.9M) | ||
| Income tax expense | 443.0K | |||
| Net Income | (332.6M) | (327.3M) | (257.6M) | (190.9M) |
| EPS | (2.3) | (2.1) | (1.3) | (0.9) |